Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lang

Showing results (401-410 of 437) with videos related to

Pageof 44
Sort By:
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
Lancet (London, England)|November 8, 2022
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R Kalra, John G F Cleland, Mark C Petrie, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Circulation|September 25, 2023
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE TrialPeter A Henriksen, Peter Hall, Iain R MacPherson, et al.
JAMA Network Open|December 3, 2025
Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical TrialCongying Xia, Amanda M Smith, Bénédicte Lefebvre, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
Cardiovascular Research|May 26, 2026
Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fractionAli Ali Mohamed Elbassioni, Anmar A Raheem, Jian Song, et al.
Circulation. Cardiovascular Imaging|July 13, 2012
In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humansJennifer M J Richards, Catherine A Shaw, Ninian N Lang, et al.
Pageof 44

Showing results (401-410 of 437) with videos related to

Sort By:
Pageof 44
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
Lancet (London, England)|November 8, 2022
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R Kalra, John G F Cleland, Mark C Petrie, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Circulation|September 25, 2023
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE TrialPeter A Henriksen, Peter Hall, Iain R MacPherson, et al.
JAMA Network Open|December 3, 2025
Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical TrialCongying Xia, Amanda M Smith, Bénédicte Lefebvre, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
Cardiovascular Research|May 26, 2026
Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fractionAli Ali Mohamed Elbassioni, Anmar A Raheem, Jian Song, et al.
Circulation. Cardiovascular Imaging|July 13, 2012
In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humansJennifer M J Richards, Catherine A Shaw, Ninian N Lang, et al.
Pageof 44